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ABSTRACT  
Objective: A simple, sensitive and specific spectrophotometric method was developed for the determination of atorvastatin calcium (ATCa) in pure 
and its pharmaceutical formulations using iodine in acetonitrile.  
Methods: The method is based on the oxidation of atorvastatin calcium by iodine and formation triiodide (I3−) complex.  
Results: The formed complex was measured at 291 and 360 nm against the reagent blank prepared in the same manner. The optimum 
experimental parameters are selected. Beer’s law is valid within a concentration range of 0.5586-11.173 μg/ml. The relative standard deviation did 
not exceed 3.0% and regression analysis showed a good correlation coefficient (R2= 0.9995). The limit of detection (LOD) and the limit of 
quantification (LOQ) were to be 0.056 and 0.17 μg/ml, respectively.  
Conclusion: The developed method is applied for the determination of atorvastatin in pure and its commercial tablets without any interference 
from excipients (at λmax =291 & 360 nm), ezetimibe (EZE), fenofibrate (FEN) and aspirin (ASP) at λmax =360 nm with average recovery of 99.45 to 
102.4%. The results obtained agree well with the contents stated on the labels. 
Keywords: Spectrophotometric method, Atorvastatin calcium (ATCa), Iodine, Triiodide complex.  
 
INTRODUCTION 
Atorvastatin calcium  is a calcium (bR, dR)-2-(r-fluorophenyl)-b, 
ddihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl) pyrrole-1-
hepatanoicacid (1:2) trihydrate. The empirical formula of 
atorvastatin calcium trihydrate is C66H68CaF2N4O10.3H2O or 
(C33H34FN2O5)2Ca.3H2O, mol. mass 1209.4 g; where the empirical 
formula of atorvastatin is C33H35FN2O5, mol. mass 558.64 g 
(Scheme1) [1]. Atorvastatin calcium is a white to off-white 
crystalline powder that is insoluble in aqueous solutions of pH 4 and 
below. Atorvastatin calcium is very slightly soluble in distilled water, 
pH 7.4 phosphate buffer and acetonitrile; slightly soluble in ethanol; 
and freely soluble in methanol. Atorvastatin is a member of the drug 
class known as statins, used for lowering blood cholesterol. It also 
stabilizes plaque and prevents strokes through anti-inflammatory 
and other mechanisms [2, 3]. Several studies have been reported for 
the determination of atorvastatin in pure form, in pharmaceutical 
formations and in biological fluids including spectrophotometric 
methods [2, 4-36], chromatographic methods with different 
detectors [37-39] and electrochemical methods analysis [40-49].  
Spectrophotometric determination of rosuvastatin calcium through 
oxidation it by iodine and formation I3− complex in acetonitrile was 
studied. It was found that only one molecule of rosuvastatin, from two 
molecules of RSV in (RSV)2 Ca, ionized and oxidized by iodine [36]. 
In chemistry, triiodide usually refers to the triiodide ion, I3− 
(Scheme2). This anion, one of the polyhalogen ions, is composed of 
three iodine atoms. It is formed by combining non-aqueous and 
aqueous solutions of iodide salts and iodine according to the 
following equation [50-57]: 
I–+I2 → I3– ……………………………………………………………….. (1)
 
  
Atorvastatin C33H35FN2O5, AT Atorvastatin calcium(C33H34FN2O5)2Ca.3H2O, ATCa 
Scheme 1: Chemical structure of atorvastatin and atorvastatin calcium 
 
 
Scheme 2: Chemical structure of triiodide, I3- 
Many pharmaceutical preparations of AT contain another drug as ezetimibe (EZE), fenofibrate (FEN) and Aspirin (ASP) in the combined dosage 
forms. In the present work, we developed (for the first time) a specific spectrophotometric method allows determination of atorvastatin calcium in 
the presence of some other drugs as EZE, FEN and ASP by oxidizing it with iodine and formation I3–complex in acetonitrile. 
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MATERIALS AND METHODS 
Instruments and apparatus 
Spectrophotometric measurements were made in PG Instruments 
Ltd model UV-Visible spectrometer T90+with 0.5 cm quartz cells. An 
ultrasonic processor model POWERSONIC 405 was used to sonicate 
the sample solutions. The solution was kept in a thermostat at 35oC. 
The diluter pipette model DIP-1 (Shimadzu), having 100 μl sample 
syringe and five continuously adjustable pipettes covering a volume 
range from 20 to 5000 μl (model PIPTMAN P, GILSON). A centrifuge 
(Centurion Scientific Ltd., Model: K2080-Manufactured in the United 
Kingdom) was used for preparation of the experimental solutions. 
Reagents 
Atorvastatin Calcium trihydrate was supplied by ind-swift (India), 
its purity as atorvastatin was 92.0%. Iodine (purity 99.8%) of 
analytical grade, acetonetrile for HPLC and methanol extra pure was 
from MERCK. All solvents and reagents were analytical grade 
chemicals. 
A stock standard solution of iodine (1x10-2 mol/l) 
Dissolving 63.58 mg of iodine with acetonitrile into volumetric flask 
(25 ml) and diluting to mark by acetonitrile. 
A stock standard solution of atorvastatin calcium (1x10-4 mol/l) 
This solution was prepared by dissolving 32.86 mg from 
atorvastatin calcium trihydrate in 1 ml methanol and diluting to 50 
ml with acetonitrile, 1x10-3 mol/l of atorvastatin (a), then diluting 
5.000 ml from this solution to 50 ml with acetonitrile, 1x10-4 mol/l 
of atorvastatin (b). The stock solutions were further diluted to 
obtain working solutions daily just before the use in the ranges of 
atorvastatin: 1, 2, 4, 6, 8, 10, 12, 16, and 20 μmol/l (0.5586, 1.117, 
2.234, 3.352, 4.469, 5.586, 6.704, 8.9386 and 11.173 μg/ml) by 
transferring the volumes: 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.6 and 2.0 ml 
from stock standard solution (b) into volumetric flask (10 ml), then 
adding 0.5 ml from stock standard solution of iodine and diluting to 
10 ml with acetonitrile.  
Sample preparation 
A commercial formulation (as tablet) was used for the analysis of 
atorvastatin. The pharmaceutical formulations subjected to the 
analytical procedures:  
(1) Ezerva tablets, Barakat pharmaceutical industries, Aleppo-Syria, 
each tablet contains: 10 mg of atorvastatin (AT) and 10 mg of 
ezetimibe (EZE).  
(2) Normostat tablets, Barakat pharmaceutical industries, Aleppo-
Syria, each tablet contains: 20 mg of AT. 
(3) Atorvatin tablets, Alpha, Aleppo pharmaceutical industries, 
Aleppo-Syria, each tablet contains: 10, 20 and 40 mg of AT.  
4) Fibator tablets, Sun Pharma, India, each tablet contains: 5 and 145 
mg of AT and fenofibrate (FEN), respectively. 
Stock solutions of pharmaceutical formulations 
20 tablets of each studied pharmaceutical formulation were 
weighted accurately, crushed to a fine powder and mixed well. A 
quantity of the powder equivalent to tenth of the weight of one 
tablet, was solved in 1 ml methanol by using ultrasonic, 10 ml of 
acetonitrile was added, filtered over a 50 ml flask and washed by the 
same solvent, then diluted to 50 ml with acetonitrile. This solution 
contains the follows: 20, 40 and 80 μg/ml for all studied 
pharmaceutical formulations contain 10, 20 and 40 mg/tab, 
respectively. 
Working solutions of pharmaceuticals 
These solutions were prepared daily by diluting 1.00, 0.50 and 0.25 
ml from stock solutions of pharmaceutical formulations, 
respectively, then adding 0.5 ml from stock standard solution of 
iodine and adjusting the volume to 10 ml with acetonitrile (each 
solution contains 2 μg/ml of atorvastatin). 
Working standard addition solutions of pharmaceuticals 
These solutions were prepared as the follows: same mentioned 
volumes of stock solutions of pharmaceuticals were taken with 0.40, 
0.80, 1.20 and 1.60 ml from stock solution (b) of atorvastatin and then 
0.5 ml from stock standard solution of iodine was added and diluted to 
10 ml with acetonitrile. These solutions contain 2.000 μg/ml of 
atorvastatin (from different pharmaceuticals) plus 2.2346, 4.469, 
6.7037 and 8.938 μg/ml of standard atorvastatin, respectively. 
Procedure 
A 10 ml volume of a solution containing an appropriate 
concentration of atorvastatin (or working solutions of 
pharmaceuticals or working standard addition solutions of pharma-
ceuticals) with appropriate amount of iodine in acetonitrile was kept 
at temperature 35±5 °C for 20 min at λmax,1= 291 nm and at λmax,2= 
360 nm was ready for spectrophotometric measurement.  
RESULTS AND DISCUSSION 
The different experimental parameters affecting on the 
spectrophotometric determination of atorvastatin calcium through 
oxidation it by iodine and formation I3− complex in acetonitrile were 
extensively studied in order to determine the optimal conditions for 
the determination of AT.  
Spectrophotometric results 
UV-Vis spectra of ATCa, Iodine, I3–complex (resulting from the 
oxidation of ATCa by iodine), ezetimibe (EZE), fenofibrate (FEN) and 
aspirin (ASP) solutions in acetonitrile were studied. The ATCa, EZE, 
FEN and ASP solutions do not absorb in range 340-600 nm, the 
values of λmax for them were 246, 220, 287 and 226 nm, and of molar 
absorptivity (ε) were 2.33x104, 2.75x104, 2.58x104 and 0.75x104 L. 
mol-1. cm-1, respectively. The iodine solutions absorb at λmax 456 nm 
(ε=830 L. mol-1. cm-1), while complex solutions of I3–have absorption 
at λmax,1 = 291 nm and λmax,2=360 nm (ε291=4.645x104 L. mol-1. cm-1 
and ε360=2.23x104 L. mol-1. cm-1). See fig. 1. 
 
Fig. 1: UV-Vis spectra in acetonitrile of: 1-2.0x10-5 mol/l of AT; 
2-5x10-4 mol/l of I2; 3,4-2.0x10-5 mol/l of AT with 5x10-4 mol/l of 
I2 (where the complex I3–is formed); 5-7: 2.0x10-5 mol/l of EZE, 
FEN and ASP, respectively. { blank is acetonitrile (1-3 & 5-7) 
and iodine solution 5x10-4 mol/l (4), ℓ =0.5 cm} 
 
The effect of temperature and time 
The effect of temperature and time on the studied 
spectrophotometric method of AT was studied at different values 
20-40 oC and 5-60 min. It was found that the value of the absorbance 
(A) was not affected by temperature between 30 to 40oC (the 
temperature 35±5 °C was used). The effect of waiting time was 
determined at temperature (35 °C). It was found that the value of 
(A) was not affected by time between 18 to 30 min (the waiting time 
20 min was used). The optimum parameters established for 
determination of AT are shown in table 1. 
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Table 1: The optimum parameters established for spectrophotometric determination of AT through oxidation ATCa by iodine and 
formation I3− complex in pure and pharmaceutical dosage forms in acetonitrile 
parameters Operating modes 
Waiting time 20 min 
Temperature of solution 35±5 °C 
CI2:CAT, M ≥10 
Solvent Acetonitrile 
λmax,1 of complex  291 nm 
λmax,2 of complex I3− 360 nm 
λmax of atorvastatin 246 nm 
Molar absorptivity of complex I3− (ε1) 4.645x104 L. mol-1. cm-1 
Molar absorptivity of complex I3− (ε2) 2.23x104 L. mol-1. cm-1 
Molar absorptivity of AT (εAT) 2.33x104 L. mol-1. cm-1 
Working λmax,1 291 nm 
Working λmax,2 360 nm 
ℓ 0.5 cm 
Spectra range 200–600 nm 
Working CI2, mol/l 5x10-4 
Beer’s Law Limit, μg/ml 0.5586–11.173 
LOD(3.3SD),  μg/ml 0.056 
LOQ (10SD),  μg/ml 0.17 
Regression equation at λmax,1=291 nm:  
Slope 0.0837 
Intercept 0.0024 
Correlation coefficient (R2) 0.9995 
Regression equation at λmax,2=360 nm:   
Slope 0.0390 
Intercept 0.0018 
Correlation coefficient (R2) 0.9992 
RSD% at λmax,1=291 nm 3.0 
RSD% at λmax,2=360 nm 3.4 
 
The effect of iodine concentration 
The effect of iodine concentration on the absorbance of formed I3–
through oxidation atorvastatin calcium by iodine was studied. It was 
found that the absorbance increased with increasing the ratio of 
CI2:CAT from 1:1 to 5:1 then stayed constant  (the ratio CI2: CAT≥10 
was used, see table 1). 
i-The first step  
 
(2) 
ii-The second step:  
4I-+4I2 → 4I3-                     (3) 
iii-The proceeds equation:  
[AT]2Ca+6I2 → [5-Oxo-AT]2 Ca+4I3-+4H+(4) 
Scheme 2: Mechanism of oxidation atorvastatin calcium by 
iodine and formation I3− complex 
Mechanism of oxidation atorvastatin calcium by iodine in 
acetonitrile 
We suggest that the mechanism of oxidation atorvastatin calcium by 
iodine and formation I3− complex in acetonitrile may take place 
according to the equations (Scheme 2), as the follows: 
Calibration curves 
The calibration curves for atorvastatin in pure form through oxidation 
ATCa by iodine and formation I3− complex showed excellent linearity over 
the concentration range of 1x10-6 to 2.0x10-5 mol/l (0.5586-11.173 
μg/ml), see fig. 2 and 3. The spectra characteristics of determination of 
ATCa solutions such as the molar absorptivity (ε), λmax, Beer's law, 
regression equations which are at λmax,1=291 nm y=0.0837x+0.0024 and 
at λmax,2=360 nm y=0.0390x+0.0018; where y=absorbance, 
x=concentration of AT in μg/ml and the correlation coefficient are 
summarized in table 1.  
Analytical results 
Spectrophotometric determination of AT through oxidation 
atorvastatin calcium by iodine and formation I3− complex within 
optimal conditions using calibration curve was applied. The results, 
which are summarized in table 2, showed that the determined 
concentration of AT was rectilinear over the range of 0.5586 to 
11.173 μg/ml with relative standard deviation (RSD) was not more 
than 3.0%.  
The limit of detection (LOD) and limit of quantification (LOQ) were 
found to be 0.056 μg/ml and 0.17 μg/ml, respectively. The proposed 
method was validated statistically and through recovery studies. 
The method was successfully applied for the determination of AT in 
pure form. The results obtained from the proposed method have 
been compared with the official RP-HPLC method [37] and good 
agreement was found between them.  
Repeatability 
The repeatability of the method was evaluated by performing 10 
repeat measurements for 8.936 μg/ml of AT using studied 
spectrophotometric method under the optimum conditions. The 
amount of AT was found to be 8.872±0.26 µg/ml and the percentage 
Ramadan et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 9, 427-433 
430 
recovery was found to be 98.79±2.4 with RSD of 0.026. These values 
indicate that the proposed method has high repeatability and 
precision for AT analysis. 
 
Fig. 2: UV-Vis spectra of 5x10-4 mol/l iodine with AT at 
concentrations as the follows: 1-0.0, 2-1.0x10-6; 3-2.0x10-6; 4-
4.0x10-6; 5-6.0x10-6; 6-8.0x10-6; 7-1.00x10-5; 8-1.20x10-5; 9-
1.60x10-5and 10-2.00x10-5 mol/l in acetonitrile { Blank: (a) 
acetonitrile and (b) iodine solution 5x10-4 mol/l, ℓ =0.5 cm} 
 
Fig. 3: Calibration curve for determination of AT through 
oxidation ATCa by I2 and formation I3− complex according to 
optimal conditions at λmax: 1-291 nm and 2-360 nm (Blank is 
iodine solution 5x10-4 mol/l, ℓ = 0.5 cm) 
 
Table 2: Spectrophotometric determination of AT through oxidation atorvastatin calcium by iodine and formation I3− complex within 
optimal conditions using calibration curve in acetonitrile 





















μg/ml (taken)  
0.557 3.0 0.569±0.021 0.0076 0.017 0.569 291 0.5586 
 3.4 0.55±0.023 0.0084 0.019 0.550 360  
1.115 3.0 1.12±0.042 0.015 0.034 1.120 291 1.117 
 3.4 1.168±0.049 0.018 0.040 1.168 360  
2.240 2.9 2.182±0.079 0.028 0.063 2.182 291 2.234 
 3.4 2.271±0.099 0.035 0.077 2.271 360  
3.362 2.8 3.376±0.12 0.042 0.094 3.376 291 3.352 
 3.4 3.265±0.14 0.050 0.11 3.265 360  
4.436 2.8 4.332±0.15 0.054 0.12 4.332 291 4.468 
 3.4 4.369±0.18 0.066 0.15 4.369 360  
5.585 2.7 5.706±0.19 0.069 0.15 5.706 291 5.586 
 3.3 5.693±0.23 0.084 0.19 5.693 360  
6.700 2.6 6.662±0.21 0.077 0.17 6.662 291 6.704 
 3.2 6.797±0.27 0.097 0.22 6.797 360  
8.901 2.4 8.872±0.26 0.095 0.21 8.872 291 8.936 
 3.0 8.784±0.33 0.12 0.26 8.784 360  
11.198 2.2 11.262±0.31 0.11 0.25 11.262 291 11.173 
 2.8 11.256±0.39 0.14 0.31 11.256 360  
* n=5, t= 2.776. 
 
APPLICATION  
Many applications for the determination of atorvastatin calcium in 
some pharmaceutical preparations (which contain ATCa only or ATCa 
with EZE or FEN or ASP) using spectrophotometric method (at λmax,1 
= 291 nm and λmax,2 = 360 nm) through oxidizing it by iodine and 
formation I3–complex in acetonitrile according to the optimal 
conditions were performed. Regression equations and correlation 
coefficients were included in table 3. Standard additional curves for 
determination of atorvastatin calcium in different pharmaceutical 
preparations were used. The standard addition curves of Atorvatin, 
tablets (Alpha 10 mg/tab.) and Ezerva, tablets (Barakat 10 mg/tab. 
of AT and 10 mg/tab. of EZE) were shown in fig. 4, as an example. 
The amount (m) of atorvastatin calcium in one tablet was calculated 
from the following relationship: m = h. m', where: m' is the amount 
of AT in tablet calculated according to the following regression 
equation: y=a.x+b; when y=0; m'=x=b/a=intercept/slope (μg/ml), h 
conversion factor is equal to 5, 10 and 20 for 10, 20 and 40 mg/tab 
of AT. The results of quantitative analysis for AT in some 
pharmaceutical preparations calculated using the standard 
additions method were summarized in table 4. Many pharmaceutical 
preparations of AT contain another drug as EZE, FEN and ASP in 
combined dosage forms. It was found that λmax,1 could be used if 
preparation contains only AT, where λmax,2 should be used for 
preparations contain EZE or FEN or ASP with AT. The proposed 
method was simple, economic, specific and successfully applied to 
the determination of AT in pharmaceuticals (at λmax,2 = 360 nm) 
without any interference. Average recovery was 99.45 to 102.4%. 
The results obtained by this method agree well with the contents 
stated on the labels and were validated by RP-HPLC [37]. 
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Table 3: Regression equations and correlation coefficients for determination of AT (individually or with EZE or FEN) in some 
pharmaceutical preparations using developed spectrophotometric method in acetonitrile at λmax291 nm and 360 nm 






Correlation coefficients Amount of AT (m), mg/tab.  
AT  EZE FEN 
Ezerva 10 10 - 291 2.357 y=0.0846x+0.1994 R2=0.9993 mAT/tab.=5m'=11.78 
   360 2.047 y=0.0400x+0.0819 R2=0.9991 mAT/tab.=5m'=10.24 
Normostat 20 - - 291 2.043 y=0.0832x+0.1700 R2=0.9994 mAT/tab.=10m'=20.43 
   360 2.033 y=0.0394x+0.0801 R2=0.9994 mAT/tab.=10m'=20.33 
Atorvatin 10 - - 291 1.991 y=0.0839x+0.1670 R2=0.9994 mAT/tab.=5m'=9.955 
   360 1.989 y=0.0397x+0.0790 R2=0.9986 mAT/tab.=5m'=9.945 
20 - - 291 2.045 y=0.0834x+0.1705 R2=0.9994 mAT/tab.=10m'=20.45 
   360 2.020 y=0.0389x+0.0786 R2=0.9994 mAT/tab.=10m'=20.20 
40 - - 291 2.012 y=0.0838x+0.1686 R2=0.9994 mAT/tab.=20m'=40.24 
    360 2.006 y=0.0391x+0.0784 R2=0.9994 mAT/tab.=20m'=40.12 
Fibator 5 - 145 291 Not determined 
    360 2.035 Y=0.0396x+0.0806 R2=0.9982 mAT/tab.=2.5m'=5.09 
*y= n A, x= concentration of atorvastatin (µg/ml)= m' = intercept/slope. 
 
Table 4: Determination of AT in some pharmaceutical preparations using spectrophotometric method through oxidation atorvastatin 
calcium by iodine and formation I3− complex in acetonitrile λmax291 nm and 360 nm 
Commercial name Contents, mg/tab.  λmax, 
nm 




Recovery % RP-HPLC [37] 
AT EZE FEN x , mg/tab RSD% 
Ezerva 10 10 - 291 11.78 3.6 117.8 10.20 2.1 
    360 10.24 3.7 102.4  
Normostat 20 - - 291 20.43 3.6 102.2 20.41 1.8 
   360 20.33 3.7 101.7  
Atorvatin 10 - - 291 9.955 3.6 99.55 9.940 2.0 
   360 9.945 3.7 99.45  
20 - - 291 20.45 3.5 102.3 20.21 1.8 
   360 20.20 3.6 101.0  
40 - - 291 40.24 3.4 100.6 40.00 1.7 
     360 40.12 3.5 100.3  
 Fibator 5 - 145 291 Not determined 5.10 2.2 




Fig. 4: The standard addition curve for determination of AT in 
Atorvatin, Alpha 10 mg/tab. AT only(1 and 2) and in Ezerva, 
Ctd. tab., Barakat, 10 mg/tab. AT and 10 mg/tab. EZE (3 and 4) 
using developed spectrophotometric method in acetonitrile at 
λmax=291 nm (1 & 3) and 360 nm (2 & 4), ℓ = 0.5 cm 
CONCLUSION 
A simple, sensitive and specific spectrophotometric method is 
developed for the determination of atorvastatin calcium in pure and 
its pharmaceutical formulations in acetonitrile. This method is based 
on the oxidation of atorvastatin calcium by iodine and formation I3− 
complex. The formed complex was measured at 291 and 360 nm 
against the reagent blank prepared in the same manner. The 
optimum experimental parameters are selected. Beer’s law is valid 
within a concentration range of 0.5586-11.173 μg/ml. The 
developed method is applied for the determination of atorvastatin in 
pure and its commercial tablets without any interference from 
excipients (at λmax =291 & 360 nm), ezetimibe, fenofibrate and 
aspirin (at λmax =360 nm) with average recovery of 99.45 to 102.4%. 
The results obtained agree well with the contents stated on the 
labels and were validated by RP-HPLC [37].  
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